Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: Retrospective analysis of effectiveness and safety

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Poeran, Jashvant ^a   Rasul, Rehana ^a   Suzuki, Suzuko ^b   Danninger, Thomas ^b   Mazumdar, Madhu ^a   Opperer, Mathias ^b   Boettner, Friedrich ^b   Memtsoudis, Stavros G ^b,c  

^a MOUNT SINAI HOSPITAL   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ARTICLE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMORBIDITY; DEEP VEIN THROMBOSIS; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL RISK; TOTAL HIP PROSTHESIS; TREATMENT OUTCOME; UNITED STATES; BLOOD LOSS, SURGICAL; CHEMICALLY INDUCED; FACTUAL DATABASE; HIP ARTHROPLASTY; MIDDLE AGED; PROCEDURES; STATISTICS; VEIN THROMBOSIS;

ADULT; AGED; ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; DATABASES, FACTUAL; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PULMONARY EMBOLISM; STATISTICS AS TOPIC; STROKE; TRANEXAMIC ACID; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOSIS;

EID: 84907359498     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4829     Document Type: Article

References (30)

1. Sharrock NE, Mineo R, Urquhart B, Salvati EA. The effect of two levels of hypotension on intraoperative blood loss during total hip arthroplasty performed under lumbar epidural anesthesia. Anesth Analg 1993;76:580-4.
2. Irisson E, Hemon Y, Pauly V, Parratte S, Argenson JN, Kerbaul F. Tranexamic acid reduces blood loss and financial cost in primary total hip and knee replacement surgery. Orthop Traumatol Surg RES 2012;98:477-83.
3. Zhang H, Chen J, Chen F, Que W. The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis. Knee Surg Sports Traumatol Arthrosc 2012;20:1742-52.
4. Huang F, Wu D, Ma G, Yin Z, Wang Q. The use of tranexamic acid to reduce blood loss and transfusion in major orthopedic surgery: a meta-analysis. J Surg Res 2014;186:318-27.
5. Zhou XD, Tao LJ, Li J, Wu LD. Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials. Arch Orthop Trauma Surg 2013;133:1017-27.
6. George DA, Sarraf KM, Nwaboku H. Single perioperative dose of tranexamic acid in primary hip and knee arthroplasty. Eur J Orthop Surg Traumatol (forthcoming).
7. Oremus K, Sostaric S, Trkulja V, Haspl M. Influence of tranexamic acid on postoperative autologous blood retransfusion in primary total hip and knee arthroplasty: a randomized controlled trial. Transfusion 2014;54:31-41.
8. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012;344:e3054.
9. Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am 2012;94:1153-9.
10. Premier. Premier Perspective Database. 2014. (www.premierinc.com/wps/ portal/premierinc/public/transforminghealthcare/improvingperformance/ servicesprograms/researchservices).
11. Memtsoudis SG, Danninger T, Rasul R, Poeran J, Gerner P, Stundner O, et al. Inpatient falls after total knee arthroplasty: the role of anesthesia type and peripheral nerve blocks. Anesthesiology 2014;120:551-63.
12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
13. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
14. Moineddin R, Matheson FI, Glazier RH. A simulation study of sample size for multilevel logistic regression models. BMC Med Res Methodol 2007;7:34.
15. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. Wiley, 2000.
16. Ury HK. Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data. Biometrics 1975;31:643-9.
17. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424.
18. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083-107.
19. Parvizi J, Mui A, Purtill JJ, Sharkey PF, Hozack WJ, Rothman RH. Total joint arthroplasty: when do fatal or near-fatal complications occur? J Bone Joint Surg Am 2007;89:27-32.
20. Kirksey M, Chiu YL, Ma Y, Della Valle AG, Poultsides L, Gerner P, et al. Trends in in-hospital major morbidity and mortality after total joint arthroplasty: United States 1998-2008. Anesth Analg 2012;115:321-7.
21. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007;89:780-5.
22. Memtsoudis SG, Sun X, Chiu YL, Nurok M, Stundner O, Pastores SM, et al. Utilization of critical care services among patients undergoing total hip and knee arthroplasty: epidemiology and risk factors. Anesthesiology 2012;117:107-16.
23. Browne JA, Adib F, Brown TE, Novicoff WM. Transfusion rates are increasing following total hip arthroplasty: risk factors and outcomes. J Arthroplasty 2013;28(8 Suppl):34-7.
24. Ahmed I, Chan JK, Jenkins P, Brenkel I, Walmsley P. Estimating the transfusion risk following total knee arthroplasty. Orthopedics 2012;35:e1465-71.
25. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
26. Memtsoudis SG, Della Valle AG, Besculides MC, Esposito M, Koulouvaris P, Salvati EA. Risk factors for perioperative mortality after lower extremity arthroplasty: a population-based study of 6,901,324 patient discharges. J Arthroplasty 2010;25:19-26.
27. Murkin JM. Lessons learned in antifibrinolytic therapy: the BART trial. Sem Cardiothoracic Vasc Anesth 2009;13:127-31.
28. Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A. Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies. BMJ 2012;345:e5798.
29. Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006;105:1034-46.
30. Mybohm P, Herrmann E, Nierhoff J, Zacharowski K. Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and epsilon-aminocaproic acid-A meta-analysis of randomised and observational trials of over 30.000 patients. PloS One 2013;8:e58009.